Key Drivers
- Strong liquidity
- Heavy dilution
- Ongoing cash burn
AIAI Summary
KARD is a fully funded, high-beta clinical catalyst play through 2027—not a balance-sheet turnaround—with upside hinging on meaningful, safe data from its three cardiovascular programs and downside driven by binary trial failures or delays that could renew dilution risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Heavy dilution
- •Ongoing cash burn
KARD's strong liquidity and low leverage are offset by zero revenue, persistent cash burn, and substantial dilution from equity financing.
Price Behavior
Key Price Behavior Insights:
- •Persistent decline
- •Support test
- •Bounce potential
KARD remains in a last-month downtrend, with $16.64 support at risk and only a potential oversold bounce unless price reclaims $18.50–$19.05.
Price fell roughly 18% over the last month
Sentiment & News
Key News Insights:
- •Strong cash runway
- •2027 data catalysts
- •Increased outreach
Kardigan's strong cash runway and 2027 clinical readouts position it for key precision-cardiology validation, with investor outreach supporting milestone visibility.
The updates are moderately positive for Kardigan, though valuation will hinge on 2027 trial results
Similar Companies in Healthcare
Other companies in the same sector with AI ratings